← Issue №20/ week of Nov 15, 2026/Esophagus/Reflux

Phase I Trial of Liquid Nitrogen Spray Cryotherapy concurrent with neoadjuvant chemoradiation for Locally Advanced Esophageal Cancer: Dose Escalation and Long-Term Overall Survival.

From GI Signals issue №20: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Esophagus/Reflux rct · n=13 · Nov 10, 2026 · Endoscopy · IF 11.8

Phase I Trial of Liquid Nitrogen Spray Cryotherapy concurrent with neoadjuvant chemoradiation for Locally Advanced Esophageal Cancer: Dose Escalation and Long-Term Overall Survival.

New evidenceesophageal cancerbiomarkerbasic science
Clinical takeawayThis phase 1 trial supports further investigation of LNSC concurrent with CRT in phase 2 trials.
What it foundLNSC concurrent with CRT achieved 70% complete clinical response and 40% overall survival at 36 months, with no grade 2 or 3 adverse events.
ContextThis is the first study to evaluate LNSC concurrent with CRT in patients with locally advanced esophageal cancer, showing feasibility and potential efficacy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Shah T … Patel B · Endoscopy · IF 11.8 · PubMed ↗Permalink
← Read the whole of issue №20 Every paper GI Signals surfaces gets a page like this one. All issues